LASALasa Supergenerics Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on LASA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
Why avoid
- • Overall evidence is weak (AlgoScore 19/100)
- • Revenue growth: -82.4% YoY
- • Profit growth: -131.0% YoY
- • RSI: 39
- • MACD: bearish
Bull case
- • Debt/Equity: 0.20
- • Promoter holding: 54.6%
- • Sector momentum: sector +6.0% (1m)
- • Beta: 0.62
Bear case
- • Revenue growth: -82.4% YoY
- • Profit growth: -131.0% YoY
- • RSI: 39
- • MACD: bearish
Key risks
- • Elevated volatility / drawdown profile — size positions accordingly
- • Weak fundamentals — technical strength may not sustain
- • Momentum is fading versus the broader market
- • Revenue growth: -82.4% YoY
- • Profit growth: -131.0% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹0.42). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.